Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.72 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.70 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 2/20 | 0.70 |
| ▸ | IL1B | P01584 | 2/20 | 0.70 |
| ▸ | BRD4 | O60885 | 1/20 | 0.70 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411837 | 0.89 | CRBN (0.70) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL14632179 | 0.89 | CRBN (0.70) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL30992940 | 0.84 | CRBN (0.65) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL30993501 | 0.84 | CRBN (0.64) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL20260446 | 0.84 | CRBN (0.67) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL29094750 | 0.84 | CRBN (0.64) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL29094759 | 0.84 | CRBN (0.67) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL20442491 | 0.84 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL19973047 | 0.84 | CRBN (0.77) | CRBNIKZF3IKZF1DDB1TNF | |
| SCHEMBL1097880 | 0.84 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080628-A1 | BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF | Biolexis Therapeutics, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, XIAP, CBL | CRBN 173/4885IKZF3 209/4885IKZF1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.